The UB publishes a catalogue of experimental models to promote transfer
Experimental biomedical models are key to advancing the study of diseases and their treatment. Nowadays, they are widely used by most pharmaceutical companies, health and life science start-ups, and university R&D laboratories worldwide.
These models make it possible to test the efficacy and safety of several compounds without jeopardizing the health of human beings. They also facilitate the study of the factors that contribute to the development of a disease, its different phases and evolution, and the search for and validation of new therapeutic targets and pathways.
In order to promote the transfer of the wide variety of experimental models developed by researchers at the University of Barcelona, the FBG has gathered some of these models in the first edition of the Catalogue of Preclinical Models in Biomedical Research. The catalogue aims to be a tool for searching and identifying the most relevant experimental model for each disease and process under study, and will be updated periodically to expand the range of models available as research progresses at the university. These include both cell-culture-based (in vitro and ex vivo) models and animal (in vivo) models. The catalogue also features two University of Barcelona research groups specialized in the generation of new experimental models: Celltec-UB and Ceremet.
The use of experimental models offers great advantages that allow the study of new therapies without jeopardizing the health of human beings and with a very high predictive value. We find a recent example of this, as well as a success story of the transfer of an experimental model, in the discovery of the impact of tobacco on the lack of effectiveness of Nintedabid, a drug used in the treatment of pulmonary adenocarcinoma. The use of preclinical models developed by the research group led by Dr. Jordi Alcaraz, from the Department of Biomedicine at the University of Barcelona, allowed the identification of the molecular mechanisms involved in the lack of effectiveness of this drug. Scientists from the University of Barcelona, the Hospital Clínic, and Boehringer Ingelheim collaborated in this study, and the discovery was published in the journal Cancer Research.